CD8+ Regulatory T Cells Inhibit GVHD While Preserving Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for controlling graft-versus-host disease (GVHD) through immune suppression in bone marrow transplantation lead to severe side effects such as tumor relapse and opportunistic infections, and they fail to maintain long-term tolerance without compromising general immunity.
Innovation Solution
The development of a method involving the generation and administration of alloantigen-specific CD8+ regulatory T cells (Tregs) using allogeneic CD40-activated B cells to induce and expand CD8hi Tregs, which can inhibit GVHD while preserving graft-versus-tumor activity and general immunity, without the need for conventional immunosuppressive drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional immunosuppressive drugs are used to control GVHD, then GVHD symptoms are suppressed, but general immunity is compromised leading to tumor relapse and opportunistic infections
Solution Approach 1:
The invention segments the immune system by specifically targeting and suppressing only the alloreactive T cells responsible for GVHD, while preserving other immune cells and functions. This is achieved through adoptive transfer of regulatory T cells that selectively inhibit donor T cell proliferation and activation against host tissues, maintaining general immunity against infections and tumors.
Solution Approach 2:
The invention uses regulatory T cells as intermediary cells to mediate between the donor immune cells and host tissues. These regulatory T cells act as a buffer that suppresses harmful alloreactive responses without requiring broad immunosuppression, thereby controlling GVHD while preserving graft-versus-tumor activity and general immunity.
2Object-affected harmful factors
If general immune suppression is applied to treat GVHD, then acute GVHD symptoms are reduced, but long-term tolerance is not maintained and side effects occur
Solution Approach 1:
The invention performs preliminary action by adoptively transferring regulatory T cells before or at the time of bone marrow transplantation. These regulatory T cells are pre-expanded and prepared ex vivo, then administered to the recipient to establish long-term immunological tolerance upfront, preventing both acute and chronic GVHD without requiring prolonged immunosuppressive therapy.
Solution Approach 2:
The invention ensures continuity of useful action by transferring regulatory T cells that provide sustained, long-term suppression of alloreactive responses. The regulatory T cells persist in the recipient and continuously maintain tolerance, eliminating the need for continuous immunosuppressive drug administration and preventing both acute and chronic GVHD phases.
3Object-affected harmful factors
If donor T cells are depleted or suppressed to prevent GVHD, then host tissue damage is reduced, but graft-versus-tumor activity is compromised
Solution Approach 1:
The invention applies local quality by directing immune suppression specifically at alloreactive T cell responses against host tissues, while preserving immune responses against tumor cells. The regulatory T cells selectively inhibit donor T cell proliferation and activation in the context of host antigens, allowing graft-versus-tumor activity to remain intact while preventing GVHD-related tissue damage.
Data Source
AI summary
Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans. The ex vivo-induced CD8hi Treg can control GVHD in an allo-specific manner by reduction of alloreactive T-cell proliferation, and inflammatory cytokine and chemokine secretion within target organs through a CTLA-4-dependent mechanism in humanized mice. Importantly, the Tregs can induce long-term tolerance effectively without compromising general immunity and graft-versus-tumor (GVT) activity.